Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Haven,
Connecticut06519

Purpose:

Lofexidine is an experimental medication that may be beneficial in reducing opiate
withdrawal symptoms, such as sleep difficulty, anxiety, and tension. The purpose of this
study is to determine whether lofexidine in combination with naltrexone can improve an
individual's ability to cope with stress and subsequently increase the chances of remaining
abstinent from opiates.

Study summary:

Naltrexone is a medication currently used to treat opiate dependence. Naltrexone blocks the
euphoric effects of opiates. However, naltrexone treatment suffers from high rates of
drop-out and relapse. One possible explanation for this is that opiate addicts continue to
experience stress in early recovery from opiate dependence. Lofexidine is an experimental
medication currently used in the United Kingdom for opiate detoxification and to treat
opiate withdrawal symptoms, including sleep difficulty, muscle pain, anxiety, and tension.
The purpose of this study is to examine whether lofexidine in combination with naltrexone
can improve an individual's ability to cope with stress. The study will examine whether
this, in turn, increases the likelihood that an individual remains abstinent from opiates
and maintains recovery for a longer time period.
Participants in this 12-week, double-blind, placebo-controlled trial will be randomly
assigned to receive either lofexidine or placebo while currently receiving standard
naltrexone outpatient treatment. Lofexidine will be initiated at twice daily doses of 0.4
mg and increased to 0.8 mg by the end of Week 1. The doses will be increased to 1.2 mg by
the end of Week 2, and maintained at this level for Weeks 3 through 12. During Week 12,
lofexidine discontinuation will be tapered over 4 days. Hour-long study visits will occur 3
times each week to assess vital signs, medication side effects, and withdrawal symptoms.
Blood, alcohol, and urine tests will be performed as well as a psychiatric evaluation.
Administration of naltrexone will also occur 3 times each week. Follow-up visits will occur
at Months 1 and 3 after discontinuation of lofexidine.

Criteria:

Inclusion Criteria:
- Meets DSM-IV criteria for opioid dependence
- Eligible to take a daily dose of 50 mg of naltrexone
- Normal EKG
- Able to read English
Exclusion Criteria:
- Currently psychotic or psychiatrically disabled (e.g., suicidal, homicidal, manic)
- Regular use of anticonvulsants, sedatives/hypnotics, prescription analgesics,
antihypertensives (including clonidine), antiarrhythmics, antiretroviral medications,
or tricyclic antidepressants
- Underlying medical conditions, such as cerebral, kidney, thyroid, or cardiac
pathology, and currently taking medications for any of these conditions
- Abstinent from opiates for more than 4 weeks prior to initiation of naltrexone
- Medical problems precluding naltrexone treatment, such as hepato-cellular injury, as
evidenced by abnormal liver enzyme tests (greater than three times the normal level)
and a history of cirrhosis
- Hypotensive (resting blood pressure below 90/50 mm Hg)
- Pregnant or breastfeeding
- Use of an investigational drug within the 3 months prior to enrollment

NCT ID:

NCT00142909

Primary Contact:

Principal InvestigatorRajita SinhaYale University

Backup Contact:

N/A

Location Contact:

New Haven, Connecticut 06519United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.